Antimicrobial resistance of Streptococcus pyogenes clinical strains;Caracteristicas de la resistencia antimicrobiana de una coleccion clinica de Streptococcus pyogenes

Salud Publica de Mexico

Volumn 42, Issue 3, 2000, Pages 226-229

  Rodríguez, Romeo S ^a   Calderón Jaimes, Ernesto ^a   Gómez Barreto, Demóstenes ^a   Espinosa de Los Monteros, Luz Elena ^a  

^a HOSPITAL INFANTIL DE MÉXICO FEDERICO GÓMEZ   (Mexico)

Author keywords

Hospitals, pediatric; Hospitals, public; Mexico; Streptococcus pyogenes drug resistance, microbial

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFACLOR; CEFEPIME; CEFOTAXIME; CLARITHROMYCIN; CLINDAMYCIN; ERYTHROMYCIN; MACROLIDE; PENICILLIN DERIVATIVE; ROXITHROMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; STREPTOCOCCUS PYOGENES; CLASSIFICATION; CROSS-SECTIONAL STUDY; DRUG EFFECT; GENETICS; HUMAN;

ANTI-BACTERIAL AGENTS; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, MICROBIAL; HUMANS; MACROLIDES; PHENOTYPE; STREPTOCOCCUS PYOGENES;

EID: 0343193143     PISSN: 00363634     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0036-36342000000300009     Document Type: Article

References (11)

1. Horn DL, Zabriskie KB, Austrian R, Cleary PP, Ferretti JJ, Fischetti VA et al. Why have group A Streptococci remained susceptible to penicillin? Report on a symposium. Clin Infect Dis 1998;26:1341-1345.
2. Shulman ST. Evaluation of penicillin, cephalosporin and macrolides for therapy on streptococcal pharyngitis. Pediatrics 1990;97:955-959.
3. Seppala H, Nissinem A, Jarvinen H, Huovinen S, HenrikssonT, Herva E et al. Resistance to erythromycin in group A Streptococci. N Engl J Med 1992;326:292-297.
4. Baquero F, Garcia-Rodríguez JA, García de Lomas J, Aguilar L. The Spanish Surveillance Group for Respiratory Pathogens. Antimicrob Agents Chemother 1999;43:178-180.
5. York MK, Gibbs L, Perdrean-Remington F, Brooks GF. Characterization of antimicrobial resistance in Streptococcus pyogenes isolates from the San Francisco Bay area of Northern California. J Clin Microbiol 1999;37: 1727-1731.
6. a edición. Washington, D.C.: American Society for Microbiology 1999; 283-296.
7. Rodríguez SR. Diagnóstico y tratamiento de las infecciones estreptocócicas. Bol Med Hosp Infant Mex 1969;26:493-502.
8. a edición. Approved Standard M7-A4.Wayne (PA): National Committee for Clinical Laboratory Standards, 1997.
9. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. Eight information supplement M100-S8.Wayne (PA): National Committee for Clinical Laboratory Standards, 1998.
10. Seppala H, Nissinen A, Yu Q, Houvinen P. Three different phenotypes of erythromicin-resistant Streptococcus pyogenes in Finland. J Antimicrob Chemother 1993;32:885-891.
11. Seppala H, Klankka T, Vuopio-Sarkila J, Muotiala A, Helenius H, Lagerk EA. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. N Engl J Med 1997;337:441-446.